The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy of vemurafenib, a selective BRAFV600E inhibitor, in combination with a MEK inhibitor in BRAFV600E colorectal cancer models.
Brian Higgins
Employment or Leadership Position - Roche
Kenneth Daniel Kolinsky
Employment or Leadership Position - Roche
Hong Yang
Employment or Leadership Position - Roche
Min Jung Kim
Employment or Leadership Position - Roche
Jia Kui Li
Employment or Leadership Position - Roche
Zenaida Go
Employment or Leadership Position - Roche
Kathryn Packman
Employment or Leadership Position - Roche
Gideon Bollag
Employment or Leadership Position - Plexxikon
Fei Su
Employment or Leadership Position - Roche